Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation

Winston, Drew J.; Yeager, Andrew M.; Chandrasekar, Pranatharthi H.; Snydman, David R.; Petersen, Finn Bo; Territo, Mary C.
March 2003
Clinical Infectious Diseases;3/15/2003, Vol. 36 Issue 6, p749
Academic Journal
In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m[SUP2] q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.


Related Articles

  • Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Shepp, David H.; Dandliker, Paula S.; Miranda, Paulo de; Burnette, Thimysta C.; Cederberg, Donna M.; Kirk, L. Edward; Myers, Joel D.; Shepp, D H; Dandliker, P S; de Miranda, P; Burnette, T C; Cederberg, D M; Kirk, L E; Meyers, J D // Annals of Internal Medicine;Sep85, Vol. 103 Issue 3, p368 

    Ten marrow transplant recipients with biopsy-proven cytomegalovirus pneumonia were treated with the acyclic nucleoside analog 9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl]guanine (BW B759U). Viruria and viremia ceased after 4 days of treatment in all patients with cultures initially positive from...

  • Late Cytomegalovirus Pneumonia in Adult Allogeneic Blood and Marrow Transplant Recipients. Nguyen, Q.; Champlin, R.; Rolston, K.; Raad, I.; Jacobson, K.; Ippoliti, C.; Hecht, D.; Tarrand, J.; Luna, M.; Whimbey, E.; Giralt, S. // Clinical Infectious Diseases;3/1/1999, Vol. 28 Issue 3, p618 

    Assesses the impact of antiviral prophylaxis months after transplantation on the frequency, timing, and outcome of cytomegalovirus (CMV) pneumonia during the first year in adult allogenic blood and marrow transplant recipients. Late occurrence of episodes; Association of late CMV pneumonia with...

  • Cytomegalovirus-Associated Tubulointerstitial Nephritis in an Allogeneic Bone Marrow Transplant Recipient. Shorr, Ronald I.; Longgo, Walter L.; Oberley, Terry D.; Bozdech, Marek J.; Walker, Duard L. // Annals of Internal Medicine;Sep87, Vol. 107 Issue 3, p351 

    Presents a medical case involving a patient with cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Information on hematuria; Profile of the patient; Treatment administered; Results of the treatment.

  • Cell Medica Raises £1.95M to Expand Cell Therapy Work. Moran, Nuala // BioWorld International;9/23/2009, Vol. 14 Issue 38, p2 

    The article reports that Cell Medica Ltd. raised 1.95 million British pounds from existing shareholders to develop further applications for its cell therapy technique for protecting patients with weakened immune systems against cytomegalovirus (CMV) infections. Cell Medica's Virus-specific...

  • Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients. McGavin, J.K.; Goa, K.L. // Drugs;Jun2001, Vol. 61 Issue 8, p1153 

    Ganciclovir is a nucleoside guanosine analogue which incorporates ganciclovir triphosphate (the active moiety) into DNA during elongation, thereby inhibiting viral replication. Comparative studies of pre-emptive and prophylactic ganciclovir therapies in bone marrow transplant (BMT) recipients...

  • Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice. Hossain, Mohammad S.; Ramachandiran, Sampath; Gewirtz, Andrew T.; Waller, Edmund K. // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Prior work using allogeneic bone marrow transplantation (allo-BMT) models showed that peritransplant administration of flagellin, a toll-like receptor 5 (TLR5) agonist protected murine allo-BMT recipients from CMV infection while limiting graft-vs-host disease (GvHD). However, the mechanism by...

  • Aerosolized Ribavirin--Induced Reversible Hepatotoxicity in a Hematopoietic Stem Cell Transplant Recipient with Hodgkin Lymphoma. Chaves, Jorge; Huen, Auris; Bueso-Ramos, Carlos; Safdar, Amar; Vadhan-Raj, Saroj // Clinical Infectious Diseases;4/15/2006, Vol. 42 Issue 8, pe72 

    We describe a case of acute hepatic toxicity associated with aerosolized ribavirin in a bone marrow transplant recipient with documented respiratory syncytial virus infection. The temporal relationship with drug administration and the liver biopsy results suggested drug-induced hepatic injury....

  • Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Lee, Je-Hwan; Choi, Seong-Jun; Lee, Jung-Hee; Kim, So-Eun; Park, Chan-Jeoung; Chi, Hyun-Sook; Lee, Moo-Song; Lee, Jung-Shin; Kim, Woo-Kun; Lee, Kyoo-Hyung // Annals of Hematology;May2005, Vol. 84 Issue 5, p321 

    We investigated the occurrence of hepatic veno-occlusive disease (VOD) after allogeneic bone marrow transplantation (BMT) in 241 adults conditioned with busulfan + cyclophosphamide at a single institute and retrospectively compared 186 patients who received oral busulfan (O-Bu group) with 55...

  • Immune Complex Glomerulonephritis Following Bone Marrow Transplantation in C3 Deficient Mice. Welch, Thomas R.; Blystone, Lisa W. // PLoS ONE;2008, Vol. 3 Issue 10, p1 

    Background: The role of circulating complement in host defense and immune disease is well established. Although a number of cells and tissues are capable of synthesizing complement components locally, the importance of such local synthesis in immune disease has been difficult to establish....

  • The Case of the Cannabis Conundrum. RICHARDSON, PAMELA // ONS Connect;Dec2014, Vol. 29 Issue 4, p11 

    The article presents a case study about the use of marijuana of a 20-year-old male patient with relapsed acute myeloid leukemia. Topics discussed include his tendency to smoke marijuana to relieve nausea due to cancer treatments, the need for oncology nurses to inform patients about the dangers...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics